Experts will discuss the use of oral, inhaled, and intravenous antibiotics for challenging pathogens that are encountered in CF: MRSA, Pulmonary Non-tuberculous mycobacteria (NTM), multi-drug resistant (MDR) Pseudomonas aeruginosa, B. cepacia complex, Stenotrophomonas maltophilia, and Achromobacter species. In addition, we will discuss the diagnosis and management of allergic bronchopulmonary aspergillosis (ABPA). The session will be practical with a focus on the approach to actual CF patients and the nuances of individual cases will be discussed. Handouts will be provided with dosing and clinical scenarios to consider oral, inhaled, and intravenous antibiotics for these pathogens.
Create an approach to asymptomatic, new MRSA infection as well as the outpatient management of chronic symptomatic MRSA infection.
Explain the importance of multiple antibiotics as well as discuss options and approach for the treatment of MDR gram negative infections.
Design & assess therapeutic options of pulmonary NTM and ABPA infections.